Cantargia receives Notice of Allowance from USPTO for expanded protection in treatment of solid tumours
Cantargia AB (“Cantargia”) has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s second, follow-up patent application in the solid tumours patent family, no. 15/196,795. Cantargia has previously received formal patent approval in the United States for use of IL1RAP as target molecule for antibody therapy of several types of solid tumours.Cantargia already holds an approved patent in the United States covering a method of using IL1RAP as target molecule for antibody treatment of solid tumours such as colon cancer,